<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="800">
  <stage>Registered</stage>
  <submitdate>9/09/2005</submitdate>
  <approvaldate>9/09/2005</approvaldate>
  <nctid>NCT00182104</nctid>
  <trial_identification>
    <studytitle>International Multi Centre Randomized Clinical Trial Of Anticoagulation In Children Following Fontan Procedures</studytitle>
    <scientifictitle>An International Multi Centre Randomized Clinical Trial Of Anticoagulation In Children Following Fontan Procedures</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Hearth and Stroke grant 1998</secondaryid>
    <secondaryid>CTMG-1998-Fontan</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Defect</healthcondition>
    <healthcondition>Triscupid Atresia</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Warfarin vs ASA

Treatment: drugs: Warfarin vs ASA


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Warfarin vs ASA in prevention of thrombosis 2 yrs after Fontan</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Identify subpopulation of Fontan pts at high risk for TEs</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Determine high risk period for TEs in first 2 yrs post Fontan</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patient is scheduled to have a Fontan or modified Fontan procedure</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Requirement for long-term anticoagulation (e.g., prosthetic heart valve, active DVT)

          2. Risk of significant bleeding or any other known medical contraindication to Heparin,
             Warfarin, or ASA.

          3. Inability to supervise therapy due to social or geographical reasons.

          4. Pregnancy or potential pregnancy during study period</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/1998</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2005</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Children's Hospital - Parkville</hospital>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Hamilton Health Sciences Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Heart and Stroke Foundation of Canada</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Compare heparin/warfarin to ASA for thromboembolic prophylaxis in the first two years
      following Fontan procedures.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00182104</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul Monagle, MD</name>
      <address>Royal Children's Hospital, Parkville, Victoria, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>